Tags

Type your tag names separated by a space and hit enter

Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer.
Prostate 2001; 47(3):222-9P

Abstract

BACKGROUND

Cytotoxic T cells (CTL) are considered one of the primary effector cell populations in antitumor immunity. Recent studies, however, have demonstrated the critical importance of helper T cells (Th), specifically interferon gamma (IFN gamma)-secreting Th1 cells, either by supporting an appropriate CTL environment or by recruiting other effector cells. We evaluated whether patients with prostate cancer have naturally occurring Th-cell responses specific for two prostate cancer-associated antigens, prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP), and whether Th1-type responses to these antigens could be detected.

METHODS

Peripheral blood mononuclear cells (PBMC) were collected from 80 patients with prostate cancer and 20 male controls without prostate disease. Th-cell responses were evaluated by measuring antigen-specific proliferation. IFN gamma and IL-5 secretion in response to antigen stimulation was determined by enzyme-linked immunosorbent assay.

RESULTS

T cell proliferative responses specific for PSA and PAP could be detected in patients with prostate cancer. Six percent (5/80) of patients had T cell responses specific for PSA and 11% (9/80) for PAP. T cell responses specific for PSA were more prevalent in patients with metastatic disease (P = 0.02), whereas responses specific for PAP could be detected in patients irrespective of disease stage. IFN gamma-producing Th cells, specific for both PSA and PAP, could be identified in patients with prostate cancer.

CONCLUSIONS

Patients with prostate cancer can have detectable Th-cell responses specific for the prostate cancer-associated proteins PSA and PAP. The presence of antigen-specific Th1 immune responses in prostate cancer patients suggests that an immune environment capable of supporting antigen-specific CTL may exist in vivo. Prostate 47:222-229, 2001.

Authors+Show Affiliations

Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington 98195-6527, USA. dmcneel@u.washington.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

11351352

Citation

McNeel, D G., et al. "Naturally Occurring Prostate Cancer Antigen-specific T Cell Responses of a Th1 Phenotype Can Be Detected in Patients With Prostate Cancer." The Prostate, vol. 47, no. 3, 2001, pp. 222-9.
McNeel DG, Nguyen LD, Ellis WJ, et al. Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer. Prostate. 2001;47(3):222-9.
McNeel, D. G., Nguyen, L. D., Ellis, W. J., Higano, C. S., Lange, P. H., & Disis, M. L. (2001). Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer. The Prostate, 47(3), pp. 222-9.
McNeel DG, et al. Naturally Occurring Prostate Cancer Antigen-specific T Cell Responses of a Th1 Phenotype Can Be Detected in Patients With Prostate Cancer. Prostate. 2001 May 15;47(3):222-9. PubMed PMID: 11351352.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer. AU - McNeel,D G, AU - Nguyen,L D, AU - Ellis,W J, AU - Higano,C S, AU - Lange,P H, AU - Disis,M L, PY - 2001/5/15/pubmed PY - 2001/6/2/medline PY - 2001/5/15/entrez SP - 222 EP - 9 JF - The Prostate JO - Prostate VL - 47 IS - 3 N2 - BACKGROUND: Cytotoxic T cells (CTL) are considered one of the primary effector cell populations in antitumor immunity. Recent studies, however, have demonstrated the critical importance of helper T cells (Th), specifically interferon gamma (IFN gamma)-secreting Th1 cells, either by supporting an appropriate CTL environment or by recruiting other effector cells. We evaluated whether patients with prostate cancer have naturally occurring Th-cell responses specific for two prostate cancer-associated antigens, prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP), and whether Th1-type responses to these antigens could be detected. METHODS: Peripheral blood mononuclear cells (PBMC) were collected from 80 patients with prostate cancer and 20 male controls without prostate disease. Th-cell responses were evaluated by measuring antigen-specific proliferation. IFN gamma and IL-5 secretion in response to antigen stimulation was determined by enzyme-linked immunosorbent assay. RESULTS: T cell proliferative responses specific for PSA and PAP could be detected in patients with prostate cancer. Six percent (5/80) of patients had T cell responses specific for PSA and 11% (9/80) for PAP. T cell responses specific for PSA were more prevalent in patients with metastatic disease (P = 0.02), whereas responses specific for PAP could be detected in patients irrespective of disease stage. IFN gamma-producing Th cells, specific for both PSA and PAP, could be identified in patients with prostate cancer. CONCLUSIONS: Patients with prostate cancer can have detectable Th-cell responses specific for the prostate cancer-associated proteins PSA and PAP. The presence of antigen-specific Th1 immune responses in prostate cancer patients suggests that an immune environment capable of supporting antigen-specific CTL may exist in vivo. Prostate 47:222-229, 2001. SN - 0270-4137 UR - https://www.unboundmedicine.com/medline/citation/11351352/Naturally_occurring_prostate_cancer_antigen_specific_T_cell_responses_of_a_Th1_phenotype_can_be_detected_in_patients_with_prostate_cancer_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0270-4137&date=2001&volume=47&issue=3&spage=222 DB - PRIME DP - Unbound Medicine ER -